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ABSTRACT 
 
Lung cancer (LC), colo-rectal cancer (CRC) and breast cancer (BC) 
are considered the biggest killers in oncology, accounting for about 
40% of cancer deaths. During the last decade, improvement in 
cancer biology knowledge led to discovery and clinical use of new 
agents specifically targeting proteins critically involved in cancer 
growth. Although these new agents, including the Epidermal 
Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKIs), 
the anti-EGFR antibodies (cetuximab, panitumumab), the anti-HER2 
antibody (trastuzumab) and the anti vascular endothelial growth 
factor (VEGF) antibody (bevacizumab), are significantly 
contributing to increase duration of life, no patient with metastatic 
disease can obtain a definitive cure. 
Available data suggest the hypothesis that cancer is driven by a small 
subpopulation of cells called “cancer stem cells” (CSCs) or “tumor 
initiating cells” with an unlimited proliferative potential and the 
ability to reproduce the original human tumor in experimental animal 
models. CSCs are responsible for tumor development, growth and 
progression. Current therapies are largely ineffective against the stem 
cell population, explaining the failure of standard treatments. In the 
present study we investigated whether CSCs isolation and in vitro 
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sensitivity assay are feasible, leading to identification of an effective 
treatment for chemorefractory NSCLC, CRC and BC.  
Patients with heavily pretreated NSCLC, BC and CRC (median of 2 
previous regimens) were included onto the study. CSCs were isolated 
from effusions or fresh cancer tissue from primary tumor or 
metastasis. Specific culture conditions select for CD133+ immature 
tumor cells. CSCs were propagated in vitro and further exposed to 
different chemotherapeutic and targeted agents. The agent or drugs 
combination inducing the highest CSCs mortality rate identified a 
possible tailored treatment. Moreover, by using cancer cell spheres, 
orthotopic xenograft models will be generated. 
The study included 23 NSCLC and CRC patients with a median age of 
66 years (range 42-85). The procedure for CSCs isolation was 
repeated in 1 patient. CSCs were obtained from liver metastases in 6 
cases (25%), lung nodule excision in 2 cases (8%), lymph node 
excision in 3 cases (12,5%) and pleural, peritoneal and pericardial 
effusion in 13 cases (54%). CSCs were successfully isolated in 15 
patients (63%). Failure in CSCs isolation was due to inadequate 
material (8 cases) or delivery accident (1 case). CSCs sensitivity assay 
was successfully performed in 7 patients (29%), with a median of 15 
drugs or combinations tested (range 5-28) and a median time required 
for results of 51 days (range 37-95). 
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Preliminary data of our study indicate that CSCs isolation and in vitro 
sensitivity assay are feasible in metastatic NSCLC. Laboratory 
procedures for chemosensitivity assessment and for characterization 
of CSCs in vitro and in vivo are currently ongoing.  
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1.0  INTRODUCTION 
 
1.1 State of the art of advanced stage lung cancer, colorectal 
cancer and breast cancer treatment 
 
In 2011, Lung Cancer (LC), colorectal cancer (CRC) and breast 
cancer (BC) remained the leading causes of cancer-related death 
worldwide [1]. For patients with metastatic disease definitive cure is 
not achievable and median survival is approximately 1 year for non-
small-cell lung cancer (NSCLC) and about 2 years for metastatic CRC 
and BC [2]. For NSCLC patients chemotherapy with third-generation 
platinum-based doublets represented the standard of care until 
recently, when major breakthroughs in the knowledge of cancer 
biology has granted the signaling out of numerous targeted therapies. 
Large phase III clinical trials demonstrated that a proper front-line 
therapy of a patient with metastatic NSCLC should de based on tumor 
histology and biology. Patients harboring activating Epidermal 
Growth Factor Receptor (EGFR) mutations benefit more from EGFR-
Tyrosine Kinase Inhibitors (EGFR-TKIs) than from standard 
platinum-based chemotherapy at least in terms of response rate, 
progression-free survival (PFS), toxicity profile and quality of life [3-
7]. Although no phase III data are currently available, patients with 
ALK translocation seem to derive a substantial and sustained benefit 
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when treated with crizotinib, an oral c-MET and ALK inhibitor [8]. In 
patients without any detectable specific target, histology is the major 
factor influencing therapy choice. Patients with non-squamous 
histology seem to benefit more from a pemetrexed-based 
chemotherapy [9], while in squamous histotype the classical 
combination of platin (cisplatin or carboplatin) together with 
gemcitabine, vinorelbine or a taxane remains the standard of care [2]. 
At the present time there are only three agents approved for second-
line therapy, including pemetrexed, docetaxel and erlotinib that is also 
the only drug approved for third-line therapy. These three agents are 
considered equally effective in unselected patients, with a toxicity 
profile in favor of erlotinib and pemetrexed [10,11].  
For CRC patients, over the past 2 decades the repertoire of 
chemotherapeutic agents has increased and extended median overall 
survival to more than 20 months. Today the active drugs for CRC 
include 5-Fluorouracyl, irinotecan, oxaliplatin and mytomicin C. An 
increasing body of evidence also supports the addition of targeted 
agents, those directed towards VEGF (bevacizumab) and EGFR 
(cetuximab, panitumumab), to expand treatment options for patients 
with metastatic disease. Bevacizumab, added to a 5-fluorouracil (5FU) 
± irinotecan-based chemotherapy as first-line treatment, has been 
shown to improve response rates and survival of mCRC patients when 
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compared to chemotherapy alone [12-14]. An improvement of PFS 
was also shown in first-line with the addition of bevacizumab to 
oxaliplatin-based chemotherapy [15]. A randomized phase III study 
also reported a clinical efficacy of the association of bevacizumab and 
FOLFOX4 as second-line in metastatic CRC patients previously 
treated with a fluoropyrimidine and irinotecan, with a significant 
improvement in response rate, PFS and OS when compared to 
FOLFOX4 alone [16]. Moreover, the benefits of cetuximab in 
metastatic CRC are well documented in clinical trials. Cetuximab  role 
is clear  not only in irinotecan-refractory or heavily pretreated patients, 
but also in addition to FOLFIRI (irinotecan/5-fluorouracil/leucovorin) 
in first-line metastatic colorectal cancer, with an enhanced effect in 
patients with KRAS wild-type tumors [17]. In these patients, a recent 
meta-analysis of the pooled Cetuximab Combined with Irinotecan in 
First-Line Therapy for Metastatic Colorectal Cancer (CRYSTAL) and 
Oxaliplatin and Cetuximab in First-Line Treatment of CRC (OPUS) 
patients populations confirms that the addition of cetuximab to first-
line chemotherapy achieves a statistically significant improvement in 
the best overall response, overall survival time, and progression-free 
survival (PSF) compared with chemotherapy alone [18].  
In metastatic BC several options are available. In HER-2 
positive patients anti-HER2 strategies, based on the use of 
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trastuzumab and lapatinib, can prolong patients life expectancy. 
Several phase III trials have demonstrated an improvement in terms of 
overall response rate, progression free survival and overall survival if 
these drugs are used in association to chemotherapy [19, 20]. In HER2 
negative hormone-sensitive patients anti-hormonal drugs, both 
steroidal and non-steroidal, are available and their efficacy have been 
widely demonstrated [21]. In triple-negative patients recent trials have 
suggested a benefit when a PARP-inhibitor (olaparib) is associated to 
chemotherapy [22]. Several chemotherapeutic agents have 
demonstrated to be active in metastatic BC: antracyclines, 
fluoropyrimidines, taxanes and vinca alkaloids, even if none of them 
has been demonstrated to improve overall survival. On the other hand, 
the role of bevacizumab is not definitively clarified: discordant results 
on survival data from the phase III trials have brought recently to 
withdrawal of bevacizumab approval from the Food and Drug 
Administration [23]. 
Although many treatment options are available for LC, CRC 
and BC, none of the above mentioned drugs is able to cure any 
patient. Invariably, all patients relapse and die for their disease, clearly 
indicating that our therapies are able to eradicate only a part of the 
tumor, the sensitive phenotype. 
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1.2 Cancer stem cells 
Cancer evolution has been historically meant as consequence of 
the competition between different cellular clones leading to the 
emergence of cell strains able to survive in particular 
microenvironments according to a Darwinian model (“clonal 
evolution model” or “stochastic model”). 
A large number of recent studies underline the importance of a 
subpopulation of cancer cells with stem-cell like features, the so-
called “cancer stem cells” (CSCs) or “tumor initiating cells”, which  
possess an unlimited proliferative potential and the ability to 
reproduce the original human tumor in experimental animal models. 
This small population is suggested to be responsible for tumor 
initiation, progression and spreading. The functional properties of 
CSCs make them able to give rise to the whole cancer population and 
explain the cellular heterogeneity of cancer [24]. It’s widely known 
that cells with different degrees of differentiation coexist within a 
tumor and this may be caused by CSCs existence [25]. In particular, 
this statement is explained by CSCs plastic behavior and self-renewal 
ability. They have, in fact, an asymmetric replicative modality: 
cellular division leads to the formation of two distinct cells, one 
retaining the parenteral phenotype and one destinated to 
differentiation. These aspects of functional biology led to postulate the 
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existence of a rigid hierarchy within the tumor, with a CSC placed at 
the top of the pyramid, operating as precursor of the entire cancer cell 
population (“hierarchical model”).  
To date the two models mentioned above (schematically represented 
in figure 1) are not in contradiction as a certain grade of genetic 
heterogeneity has been described also at the top of the tumor pyramid, 
suggesting a clonal evolution also in the stem compartment [26].  
 
 
Figure 1. Two alternative models explaining tumors initiation and 
development. 
 
CSCs are thought to be the result of acquired epigenetic and 
genetic alterations that can forge signaling pathways controlling 
proliferation, differentiation and apoptosis. Such mutations would be 
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passed on to all of the stem cells’ progeny, allowing evolution towards 
malignancy.  Evidence for the existence of CSCs was obtained first in 
the context of acute myeloid leukemia and thereafter in breast, colon, 
brain, prostate, ovarian tumors and melanoma [27-32]. The bio-
pathology lab of our cooperative group characterized CSCs as CD133 
positive cells and showed that these cultured cells retain the cancer-
initiating potential upon injection into immune-deficient mice [33,34]. 
When injected in laboratory animals, CSCs exactly reproduce the 
parental tumour phenotype, not only histologically but also 
molecularly, and this feature makes them a good candidate for 
preclinical studies. In particular, tumor generated by CSCs in 
immuno-deficient mice replicate more faithfully the human origin 
tumor in terms of activation/deactivation of pro-tumorigenic processes 
pathways than the commercially available cell lines. This 
characterization has been performed with a high-throughput 
technology, called Reverse Phase Phosphoprotein Microarray 
(RPPM), that can estimate the state of activation of hundreds of 
molecular endpoints involved in key biological processes like 
uncontrolled proliferation, apoptosis, DNA repair mechanisms, self-
renewal and epithelial to mesenchymal transition. It has been 
demonstrated that, if kept in culture for more than one year, the 
xenografts originated by CSCs maintain the same molecular signature 
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of the original tumor (figure 2) [35]. In conclusion, CSCs can be 
maintained in vitro indefinitely without losing their features and this 
charachteristic, in association with the possibility of propagating them 
in the experimental animal, make these cells a wonderful tool for a 
possible personalization of cancer treatment.  
 
 
 
 
Figure 2. Venn diagram showing the percentage of molecular 
endpoints resulting by the comparison of patient’s tumor with 
xenografts obatained by CSCs (left) e by commercial cell lines 
(right). 
 
Recent studies have revealed that CSCs produce high levels of 
anti-apoptotic proteins and growth factors making them refractory to 
antineoplastic treatments. Tumors have been widely described to 
evade death signals generated by therapeutic drugs through the 
development of anti-apoptotic mechanisms, but the molecular bases of 
chemotherapy failure has not yet been defined in the majority of 
tumors. One particularly intriguing property of CSCs is that they are 
highly resistant to drugs and toxins because of the expression of 
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several ABC transporters and anti-apoptotic factors and an active 
DNA-repair capacity [36]. Moreover, recently it has been shown that 
the apparent tumor debulking, obtained by chemotherapy, 
paradoxically causes the enrichment of the stem pool [37]. In addition, 
chemotherapeutic agent are directed at killing rapidly dividing cells, 
while CSCs are relatively slow cycling like normal stem cells. The 
inefficacy of conventional therapies towards the stem cell population 
might explain cancer chemoresistance and the high frequency of 
relapse shown by the majority of tumors. Therefore, the selective 
targeting of these cells appears necessary to eradicate tumors and 
prevent their recurrence.  
 
1.3 Chemosensitivity assays 
Although the great effort in the development of in vitro assays able to 
define sensibility/resistance to chemotherapeutic agents, conflicting 
results have been generated [38]. Kern and Weisenthal developed an 
assay to predict an extreme resistance (Extreme Drug Resistance, 
EDR) to chemotherapy in several solid tumors [39]. In this assay 
human cancer cells were cultivated in vitro and exposed to 
chemotherapeutic agents doses proportionally much superior than 
those used in clinical practice. Cancer cells surviving to this treatment 
show a condition of EDR. On the basis of these data it was suggested 
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that, in presence of a condition of EDR, this assay may have a 
negative predictive value. A great number of studies evaluated the 
technical aspects of the EDR assay and its correlation with response; 
anyway, only a little number of studies compared EDR-guided 
treatment to standard chemotherapy [38, 40, 41]. Due to conflicting 
results, lack of randomization and of long-term outcomes evaluation, 
in 2004 the American Society of Clinical Oncology (ASCO) did not 
recommend EDR as a possible tool guiding chemotherapy in clinical 
practice. In 2006 a multicenter randomized trial assessed the impact of 
EDR-guided chemotherapy (experimental arm) in confront of standard 
chemotherapy (control arm) in the first-line treatment of ovary cancer 
patients. An interim analysis of this study has not demonstrated a 
superiority for the experimental arm. Taken together, these data 
suggest that EDR test has a limited impact on predicting response to 
chemotherapy. In vitro drug sensitivity assays failure might be 
explained by the missing of the real target, that is the CSC. Only the 
elimination of these cells can theoretically bring to durable disease 
remissions.  
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2.0 STELLA: A FEASIBILITY STUDY ON STEM CELLS 
SENSITIVITY ASSAY 
 
2.1 Rationale 
1) LC, CRC and BC are major killers in oncology, accounting for 
about 40% of cancer deaths. Although progresses have been made in 
the last few years, unfortunately no patient with metastatic disease can 
obtain a definitive cure. 
2) A recent  hypothesis is that cancer is driven by a small  
subpopulation of cells called “cancer stem cells” (CSCs) with an  
unlimited proliferative potential and the ability to reproduce the 
original human tumor in experimental animal models. These cells are 
thought to be responsible for tumor development, representing the 
only cell population able to sustain tumor growth and progression. 
Current therapies are largely ineffective against the stem cell 
population, explaining the failure of standard treatments. 
3) To date chemosensitivity assays studies failed in evidencing a 
predictive value. The failure may be explained by the missing of the 
real target, the CSCs. 
4) Current  technologies  allow  us  to  isolate  and  expand  in  vitro  
the  CSCs  from  tumor specimens, testing in vitro their sensitivity to 
 16 
different anticancer drugs. Therefore,  there  is  the  potential  
opportunity  to  identify  and  offer  an  individualized therapy to LC, 
CRC and BC patients. 
5) Pathways responsible for CSCs homeostasis and global analysis 
can be analyzed (phosphoproteomic and signal transduction analysis, 
innovative drug testing, analysis of metastatization processes in vivo) 
in order to provide an overall picture of their activation state. 
6) Orthotopic xenografts can be generated by CSCs modified in order 
to express a bioluminescent protein (luciferase). This may allow CSCs 
tracking in vivo. The local tumor and the invasiveness development 
will be monitored through whole-body imaging techniques. Non 
anesthetized and freely moving animals can be analyzed by this 
thecnique. Xenograft tumor can be removed for phosphoproteomic 
analysis. This system can provide information on specific molecular 
pathways involved in stem cells growth and spreading. 
 
 
 
2.2 Study end-points 
Primary: 
1. To evaluate the feasibility of the project in clinical practice. 
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Secondary: 
1. To identify LC, CRC and BC stem cells. 
2. To investigate the sensitivity to anti-tumor agents in vitro. 
3. To identify drugs potentially effective for a specific patient 
 
2.3 Patients selection criteria 
Inclusion criteria 
• Histologically/cytologically confirmed diagnosis of 
metastatic NSCLC, CRC and BC. 
• Availability of tumor tissue suitable for CSCs extraction. 
• Performance status of 100% according to Karnofsky score 
(appendix I). 
• Failure of conventional therapies or no therapy of proven 
efficacy. 
• Adequate hematological, renal and liver functions. 
• No concomitant comorbidity potentially interfering with the 
study. 
• Informed consent form signature. 
• If female: childbearing potential either terminated by 
surgery, radiation, or menopause, or attenuated by use of 
approved contraceptive method (intrauterine contraceptive 
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device (IUD), birth control pills, or barrier device) during 
and for three months after trial. 
 
Exlcusion criteria 
• No possibility to obtain fresh tumor tissue.  
• Performance status <100% according to Karnofsky score. 
• Patient suitable for standard therapies.  
• Important comorbidity interfering with the study. 
• Significant alteration of liver, hematological or renal 
function(s). 
• No informed consent form signature. 
 
2.4 Study design 
The STELLA trial (Clinical Trials.gov: NCT01483001) was a 
prospective study assessing feasibility of individualized therapy in 
LC, CRC and BC patients. LC,  CRC and BC patients with good 
performance status and tumor tissue collected before study 
enrollment, at failure of conventional therapies or without possibility 
to be treated with therapy of proven efficacy, were considered 
eligible for the study. Before study entry tumor tissue was collected, 
i.e tissue obtained during a diagnostic or therapeutic procedure, like 
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surgery or biopsies with other purposes than the protocol. In vitro 
tumor sensitivity to chemotherapy drugs was tested on tumor cell 
cultures per each patient. Drugs and their combinations were 
considered effective if they kill ≥ 60% of tumor stem cells in vitro 
test. During the period between collection of samples and assay 
results, the patient can be exposed to other therapies. 
 
2.5 Experimental procedures 
CSCs identification 
Isolation and characterization of CSCs was made starting from 
samples of tumor tissue obtained from patients with LC, CRC and BC 
before study inclusion. The surgical/bioptical samples collected were 
classified according to the specific histological and molecular 
characteristics of the tumor. From each sample, by means of 
enzymatic and mechanical procedures, the CSCs were obtained and 
then cultivated in adequate culture mediums to be subsequently used 
for biochemical and molecular studies. Each sample was associated 
with the patient history at the surgical time and an appropriate follow-
up program consisting of periodic clinical and instrumental controls 
that in order to assign a prognostic value to the biological 
characteristics of the CSCs. Cells derived from the selected epithelial 
tumors then underwent analysis of surface and intracellular markers in 
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order to provide a definitive characterization of cellular phenotype. 
Stem cells derived from LC, CRC and BC were identified as a subset 
of tumor cells positive for the marker CD133.  
Tumor specimens were washed several times and left over night 
in DMEM:F12 medium supplemented with high doses of 
Penicillin/Streptomycin and Fungizone in order to avoid 
contamination. Tissue dissociation was carried out by enzymatic 
digestion and recovered cells cultured in serum-free medium 
containing 25 µg/ml insulin, 100 µg/ml apo-transferrin, 10 µg/ml 
putrescine, 0.03 mM sodium selenite, 20nM progesterone, 0.6% 
glucose, 5mM hepes, 0.1% sodium bicarbonate, 0.4% BSA, glutamine 
and antibiotics, dissolved in DMEM-F12 medium and supplemented 
with 20 ng/ml EGF and 10 ng/ml bFGF. Flasks non-treated for tissue 
culture were used in order to reduce cell adherence and favourite 
growth of undifferentiated tumour-spheres. These culture conditions 
select for immature tumor cells, while non malignant or differentiated 
cells are negatively selected as assessed for CSCs of different origin 
[30]. Surviving immature tumor cells slowly proliferate giving rise to 
tumour cell aggregates, “spheres”, within 1-2 months in these culture 
conditions. Sphere-forming cells can be expanded by mechanical 
dissociation of spheres, followed by re-plating of single cells and 
residual small cell aggregates in complete fresh medium (figure 3).  
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Differentiation of NSCLC, CRC and BC sphere-forming cells 
was obtained by cell culture in specific medium (Cambrex). 
Phenotype of NSCLC, CRC and BC spheres and their differentiated 
progeny will be analyzed by flow cytometric analysis or 
immunofluorescence. In particular stem cell markers such as CD133, 
CD34 and BCRP1 were analyzed. 
In a second step of the trial, cancer spheres will be analyzed in 
order to define the status of pathways involved in the process of 
proliferation, self-renewal and survival. In particular, tumor-specific 
analysis will be carried out to investigate the activity and the possible 
alteration of pathways responsible for stem cell homeostasis and 
global analysis (phosphoproteomic and signal transduction analysis, 
innovative drug testing, analysis of processes metastatization in vivo) 
aimed to provide an overall picture of the activation state of the key 
cellular pathways. 
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Figure 3. Isolated CSCs in different stages of culture. 
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Preclinical model 
By using cancer spheres we will generate orthotopic xenograft 
models that recapitulate the parental tumor behaviour, including the 
aggressive features and the invasiveness potential. Orthotopic 
injection technique will be assessed in 5 weeks-old NOD/SCID mice. 
The injection procedure will be done with the support of a dissecting 
microscope. After anesthetization, 200 to 500 cancer sphere cells, 
modified in order to express a bioluminescent protein such as 
luciferase will be injected using a Hamilton syringe and 32-gauge 
needle. Metastatic and local tumors will be compared for their stem 
cell content through phenotypic analysis such as growth rate, or other 
stem cell properties including clonogenic capacity in soft agar or 
through limiting dilution assays. Infection of CSCs with lentiviral 
vector, coding for green fluorescent (GFP), as well as luciferase 
reporter proteins, will allow CSCs tracking in vivo. Particularly, the 
amphotropic packaging cell line 293T will be transfected by the 
calcium-phosphate/chloroquine method. Culture supernatants 
containing viral particles will be collected after 48 hours of 
transfection. Infection will be performed by culturing target cells in 
0.45 µm filtered viral supernatant for 3 hours in a CO2 incubator. Two 
infection cycles will be performed to infect cells. Microscopic 
evaluation of GFP expression in viral packaging and target cells will 
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be performed by direct observation of cells using a reversed 
fluorescence microscope equipped with a FITC filter. After infection, 
cells transduced with luciferase will be sorted by flow cytometry to 
obtain a pure marked population. The local tumor and the 
invasiveness development will be monitored through whole-body 
imaging techniques, that will permit to detect, localize and quantify 
dynamically the optical signal - bioluminescence - in a non invasive 
localization of the marked cell population. This procedure will be 
performed using the Photon imager in vivo imaging system (Biospace 
Lab), assisted by the most recent software for acquisition and image 
analysis. Thanks to this system, characterized by a very high 
sensitivity and 20 ms temporal resolution, we will analyze non 
anesthetized and freely moving animals. The bioluminescence signal 
will be acquired simultaneously as a standard video of the animal. 
Once we are sure of the success of tumour growing, mice will be 
sacrificed. Tumor will be removed for morphological characterization 
and phosphoproteomic analysis. This latter will be performed through 
RPPM, which allows the achievement of a high degree of sensitivity, 
precision and linearity, making possible to quantify the 
phosphorylated status of signal proteins in immature and differentiated 
lung cancer cells. This system will provide information on specific 
molecular pathways involved in stem cells growth and spreading. 
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Chemosensitivity assay 
To selectively discriminate the effective therapeutic 
compounds against the putative tumor and initiating cells, we 
measured the viability of clonogenic LC, CRC and BC after the 
exposure to several  anti-tumor drugs differentially combined at 
singular time point up to 96 hours. The measure is perfomed by 
staining with acridine orange: the green colour express cell vitality, 
while apoptotic cells appear orange/red (figure 4). The choose of 
drugs and combination groups to be tested i s  defined by the 
clinician, according to histological and biological features of the 
primary tumor. 
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a)                                                                         b)                                                                                    
 
 
 
 
 
 
c)                                        
 
 
 
 
 
 
 
Figure 4. Staining with acridine orange after exposition to 
chemotherapeutic agents. a) Low sensitivity. b) Average 
sensitivity. c) High sensitivity.  
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3.0 RESULTS 
3.1 Patients characteristics 
Twenty-three patients were enrolled onto the study. Median age 
was 66 years (range: 42-85), 15 patients were male (65%) and 8 
female (35%). All subjects (100%) had a performance status of 100% 
according to Karnofsky score. Eighteen patients (78%) were affected 
by LC and their histotype was adenocarcinoma in 13 cases, squamous 
cell carcinoma in 1 case, undifferentiated NSCLC in 1 case and SCLC 
in 3 cases. Three patients (13%) had a CRC and 2 patients (9%) had 
another gastrointestinal cancer (1 small intestine adenocarcinoma and 
1 pancreas adenocarcinoma). No patient enrolled into the study was 
affected with BC. Among LC patients, 4 subjects (17%) harboured an 
EGFR mutation, 1 (4%) an ALK translocation and 1 (4%) a KRAS 
mutation. Two (6%) of the three CRC patients harboured a KRAS 
mutation. Patients were heavily pretreated, with a median of previous 
treatment lines of 2 (range: 0-7). Collection of cancer tissue or 
effusion was performed 24 times (in one LC patient material collected 
by liver biopsy was not adequate and an additional thoracentesis was 
performed). Tumor sample for CSCs isolation was obtained from liver 
metastases in 6 cases (25%), lymph node biopsy in 3 cases (12,5%), 
lung nodule excision in 2 cases (8%) and by pleural/ 
peritoneal/pericardial effusion in 13 cases (54%). 
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Number of patients 23 
Median age (range; years) 66 (42-85) 
Sex 
Male 
Female 
 
15 (65%) 
8 (35%) 
Primary cancer 
Lung Cancer 
Colorectal Cancer 
Breast Cancer 
Other 
 
18 (78%) 
3 (13%) 
0 
2 (9%) 
Histology 
Adenocarcinoma 
Squamous cell carcinoma 
Small cell carcinoma 
Other 
 
18 (78%) 
1 (4%) 
3 (13%) 
1 (4%) 
Molecular alteration 
EGFR mutation 
ALK translocation 
K-RAS mutation 
 
4 (17%) 
1 (4%) 
3 (13%) 
Number of tissue/effusion collections 24 
Specimen collection site 
Liver biopsy 
Lymph node biopsy 
Lung nodule excision 
Ascitis/pleural/pericardial effusion 
 
6 (25%) 
3 (12,5%) 
2 (8%) 
13 (54%) 
 
Table 1. Patients characteristics 
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3.2 CSCs isolation  
LC, CRC and BC patients with progressive disease after 
standard treatments and for whom the clinician requested a new tumor 
specimen collection for the evaluation of biological features, were 
identified at the Oncology Department of Livorno Civil Hospital, 
Italy. Due to the evidence of good results with cancer effusions, 
patients with ascitis, pleural and pericardial effusions were included 
into the study. In presence of effusions, it was given priority to the 
collection of these kind of samples. Specimens collection was 
executed preserving sterile conditions. 
 Effusions were centrifugated at 2500 rpm for 20 minutes and, 
after eliminating the supernatant, 3 ml of 9% saline solution was 
added. Liver, lymph node and lung biopsies were added with 3 ml of 
9% saline solution. Samples were stored up at 4°C and then shipped at 
room temperature to the Cellular and Molecular Pathophysiology 
Laboratory of the University of Palermo, Italy. Delivery took up to 24 
hours. Samples collected on Wednesday were stored at 4°C till the 
next Monday.  
 CSCs isolation was feasible in 15 cases (63%) of the 24 
procedures. Main reasons for CSCs isolation failure (9 cases, 37%) 
included inadequate material (8 cases) and delivery accident (1 case). 
No sample was lost due to contamination. CSCs isolation failure was 
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more common with biopsies (5 failures on 11 cases, 45%) than with 
effusions (3 failures on 13 cases, 23%). In particular, lymph node 
biopsy seems to be the worse tissue for CSCs isolation (2 failures on 3 
cases, 67%), while malignant effusions seems to be the samples with 
the best yield (3 failure on 13 cases, 23%) (figure 5). 
 
Figure 5. CSCs isolation failure rate according to cancer 
specimens collection site. Failed procedures are represented in 
red, while successful isolation in blue. 
 31 
According to the primary cancer, CSCs isolation failed in 5 of 15 
cases (30%) of LC, in 2 of 3 cases (67%) of CRC and in 2 of 2 cases 
(100%) of other gastrointestinal malignancies. 
  
3.3 Chemosensitivity assay 
To date chemosensitivity assay was perfomed in 7 cases (29%). 
This data is not definitive, because other tests will be perfomed as 
soon as CSCs will be disposable. All tested patients had LC, 
specifically 5 patients had a lung adenocarcinoma, 1 patient an 
undifferentiated NSCLC and 1 patient a SCLC. According to site of 
specimens collection, the starting sample was a malignant effusion in 
4 cases, a lung nodule in 1 case, a lymph node biopsy in 1 case and a 
liver biopsy in 1 case. The median time between sample collection and 
chemosensitivity assay results was 51 days (range: 37-95). The 
number of testable drugs and combinations depended on the number 
of available CSCs. In the study a median of 15 tested treatments 
(range: 5-28) was registered. In 6 of the 7 perfomed assays, no drug or 
combination showed a CSC mortality superior to 50%. In one case 4 
regimens produced a CSC mortality superior to 50% and 1 
combination gave a mortality of 80%. Figure 6 shows an example of 
the assay results received by the clinician. On the basis of these results 
the clinician might choose a personalized treatment for the patient. 
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Figure 6. Chemosensitivy assay results. a) Assay showing 
sensitivity to none of the tested  drugs. b) Assay showing several 
grades of sensitivity to the tested agents. 
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3.4 Patients treatment 
Our trial was a feasibility study and the correlation between 
sensitivity assay result and treatment outcome was not an end-point. 
No patient enrolled onto the study has been so far treated according to 
chemosensitivity assay results. In particular, one patient did not 
receive the tailored treatment because the chemosensitivity assay did 
not evidence any cell mortality when CSCs were exposed to drugs. 
One patient died before assay results, while the other patients are 
currently in treatment with chemotherapeutic/biological agents and are 
not yet in progression.  
In a preliminary experience a young patient was treated with a 
sensitivity assay tailored treatment. He was a 26 years old man with a 
metastatic squamous cell lung carcinoma diagnosed two years before. 
After four months since surgery, the disease progressed and liver and 
lung metastases were detected. Molecular analysis revealed wild type 
EGFR, KRAS and HER-2 gene status and absence of EML4/ALK 
rearrangement. He had received three treatment lines 
(cisplatin/gemcitabine, carboplatin/paclitaxel and docetaxel), when he 
presented to our institution, asking for a valid treatment option. His 
clinical conditions were good (performance status: 0) and he 
complained of epigastric pain and moderate asthenia. CT scan showed 
bilateral lung metastases and an impressive liver involvement (figure 
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7a). We proposed the patient to undergo a liver biopsy, in order to 
collect fresh tumor tissue for CSCs isolation and in vitro 
chemosensitivity assay. After about 40 days since biopsy, the biologist 
tested six combinations of antiblastic agents and the combination of 
paclitaxel and oxaliplatin demonstrated to be the most active regimen, 
causing 95% of cells death in vitro. The patient received oxaliplatin  
130 mg/mq day 1 and paclitaxel 175 mg/mq day 1 every three weeks 
for six cycles. After two cycles, a chest/abdomen CT scan surprisingly 
showed a notable reduction of liver involvement (figure 7b). 
Treatment was continued and the CT scans after the fourth cycle 
showed further improvement in liver disease (figure 7c). 
Unfortunately the disease progressed after the sixth cycle. Thanks to 
the tailored treatment, it was possible to reach a time to progression of 
4 months and a considerable liver metastases debulk with a 
symptomatic benefit. This is a remarkable result, if we consider 
patients histology and previously received treatment lines. The 
sensitivity assay tailored treatment indicated a mortality percentage of 
95%; it can be supposed that 5% of cells were resistant to the drugs 
indicated by the test and were responsible for disease progression.   
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Figure 7. A case report of a young patient treated with CSCs 
sensitivity assay tailored therapy. a) Sensitivity assay results. b) 
Basal assessment. c) Response after two cycles. d) Response after 
four cycles. 
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3.5 Laboratory experiments 
 To date laboratory experiments have not yet started. 
Cancer spheres will be analyzed in order to define the status of 
pathways involved in the process of proliferation, self-renewal and 
survival. Moreover, we will generate orthotopic xenograft models for 
morphological characterization and phosphoproteomic analysis. The 
latter will be performed through RPPM, in order to quantify the 
phosphorylation status of signal proteins in immature and 
differentiated cancer cells. Through these experiments we will acquire 
a large number of info about CSCs features and the pathways they 
preferentially use to escape apoptosis signals and drugs cytotoxicity. 
The identification of a preferential pathway would be of great interest, 
because it would open the door to research on specific anti-CSCs 
drugs.  
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4.0 CONCLUSIONS 
 LC, CRC and BC are the most common cancer worldwide and 
account for about 40% of cancer-related deaths. Many progresses in 
the treatment of these diseases have been made in the last few years. 
The strict collaboration between basic researchers and clinicians has 
permitted the signaling out of fundamental pathways used by cancer 
cells. This led to design an impressive number of target agents and to 
large studies assessing their activity and efficacy. Although progresses 
have been made, no patient can be cured even by this new agents. A 
possible explanation of this statement probably stays in the missing of 
the real target. Till the present moment, researchers based their studies 
on the differentiated pool of cancer cells. These cells usually respond 
to treatments and in clinical practice complete and partial responses 
are commonly achievable, although no metastatic patient will reach a 
definitive cure. CSCs are resistant to many chemotherapeutic and 
biological agents and a complete elimination of these cells is difficult 
to reach. In our study we evaluated if it is possible to isolate CSCs and 
proceed to a chemosensitivity assay in vitro. The initial protocol 
contemplated the enrollment of LC, CRC and BC without standard 
treatment chances. No patient enrolled into the study had BC and this 
may be explained by the large number of drugs and hormones 
disposable for BC treatment. Among NSCLC patients enrolled into 
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the study, we had 4 patients with EGFR mutations (29%) and 1 patient 
harboring a KRAS mutation (7%), far from the percentages of 
mutations found in clinical practice (15% for EGFR mutations and 
25% for KRAS mutation). The presence of EGFR mutation is an 
important prognostic factor and mutated subjects usually keep good 
clinical conditions for a long time. Conversely, KRAS mutated 
subjects have a more aggressive disease in confront of patients 
harboring EGFR mutations. We can postulate that the difference in 
genetic alterations percentage between our study and real world, is 
consequence of the strict selection criteria of the study. In fact, it was 
not possible to enroll patients with a Karnofsky performance status 
inferior to 100% and all patients must have already received all 
standard treatments. For CRC patients, two of the three patients 
enrolled harbored a KRAS mutation and this may depend on the 
reduced pool of drugs disposable for KRAS-mutated patients. The 
little number of CRC patients enrolled may depend on the lack of need 
for repeating biopsy in these subjects. To date, in fact, rebiopsy of 
CRC is of poor interest.  
 As for the biologic material used for CSCs isolation, we found 
that the best yield was obtained with malignant effusions. This is an 
important data, because thoracentesis and paracentesis are less 
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invasive than liver biopsies or lung nodule excision and are often 
necessary for symptoms relief.  
 In our study CSCs sensitivity assay has been performed in 7 
cases, that is about 1 patient every 3. The last patient was enrolled 
onto the study at the end of January and the procedure for isolation 
and in vitro expansion are currently ongoing. Therefore, to date, the 
number of feasible sensitivity assays is underestimated. The median 
time between collection and results was 51 days. It’s possible to 
reduce this time if the oncology department and the laboratory are 
closest. In our study laboratory procedure were executed in Palermo 
and this may have altered results. If it was possible to eliminate 
shipment time and to facilitate the communication between clinician 
and biologist, time required to obtain a response may reduce. 
Moreover, in the study only in one case the test revealed a CSCs 
mortality superior to 80%. In all other patients the sensitivity assay 
results were disappointing. As seen above, chemotherapy exposure 
select for a bigger pool of  resistant CSCs. The strong pre-treatment of 
our patients may be the cause of the unsuccessful test results. An 
earlier test may reduce the failure in identifying an active treatment. 
Another issue concerning the sensitivity assay is the choose of the 
drugs to be tested. In the STELLA trial the clinician empirically chose 
the drugs for the assay on the basis of tumor histology and molecular 
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status and, when a limited number of combinations were testable, the 
choose was difficult. A deeper knowledge of CSCs and of the 
pathways they use to overcome resistance and stay alive may help us 
in selecting the drugs to be tested. Predictive value of the test was not 
defined in this study. The trial was designed to evaluate the feasibility 
of the procedures of CSCs isolation and sensitivity assay in clinical 
practice. In our experience we assessed that these procedures are 
feasible and  that a major skill in selecting patients, choosing tumor 
specimen collection sites, samples storing and selecting drugs to be 
tested may improve results. The STELLA trial permitted us to identify 
a percentage of successful CSCs isolation and sensitivity tests and to 
design a phase II trial. This study will recruit NSCLC patients in 
earlier treatment stages and its primary end-point will be the 
evaluation of the predictive value of CSCs sensitivity assay. 
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APPENDIX I - Karnofsky performance status scale 
 
GRADE 
(%) 
STATUS 
100 Normal, no complaints, no evidence of disease 
90 Able to carry a normal activity: minor signs or 
symptoms of disease 
80 Normal activity with effort: some signs or symptoms of 
disease  
70 Cares for self: unable to do normal activity or to do 
active work 
60 Requires occasional assistance but is able to care for 
most of his/her needs 
50 Requires considerable assistance and frequent medical 
care 
40 Disabled: requires special medical care and assistance 
30 Severely disabled: hospitalization is indicated although 
death is not imminent 
20 Very sick: hospitalization necessary, active supportive 
treatment necessary 
10 Moribund: fatal processed 
0 Death 
 
Per gentile concessione di Karnofsky et al: The use of the 
nitrogen mustards in the palliation treatment of carcinoma with 
particular reference to bronchogenic carcinoma, Cancer 
1:634-656, 1948. 
 
 
 
